KNSA
NASDAQ HealthcareKiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares
Drug Manufacturers - Specialty & Generic
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
๐ Market Data
| Price | $55.27 |
|---|---|
| Volume | 854,206 |
| Market Cap | 4.25B |
| Beta | 0.060 |
| RSI (14-Day) | 70.0 Overbought |
| 200-Day MA | $40.40 |
| 50-Day MA | $46.52 |
| 52-Week High | $55.28 |
| 52-Week Low | $24.85 |
| P/E Ratio | 60.74 |
| Forward P/E | 37.43 |
| Price / Book | 7.43 |
๐ฏ Investment Strategy Scores
KNSA scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (83/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Moon Shot (5/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find KNSA in your text
Paste any article, transcript, or post โ the tool will extract KNSA and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.